Strong Q1 sales of $137.3M showcase Madrigal Pharmaceuticals, Inc.'s Rezdiffra's growth in non-cirrhotic NASH. Click for my ...

Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in the Canaccord Genuity 45th Annual Growth Conference on Tuesday, Aug. 12, 2025 at 10:30 A.M. EDT. The ...

Madrigal Pharmaceuticals (MDGL) stock gains as the company's Q2 2025 results exceed expectations with a 15-fold surge in ...

Second-quarter 2025 Rezdiffra™ (resmetirom) net sales of $212.8 millionAs of June 30, 2025, more than 23,000 patients on Rezdiffra Received new U.S. Rezdiffra patent providing protection to Feb. 4, ...

The idea is that SYH2086 can be paired with Rezdiffra, a selective thyroid hormone receptor agonist that became the first FDA-approved drug for metabolic dysfunction-associated steatohepatitis (MASH) ...

Madrigal will study SYH2086 in combination with Rezdiffra for metabolic dysfunction-associated steatohepatitis, aiming for ...

Madrigal Pharmaceuticals Inc.’s long-awaited business development pact became reality by way of an exclusive global license ...

The company formerly known a Sosei Heptares unveiled new weight loss programs. Elsewhere, BridgeBio and Madrigal unveiled ...

Madrigal Pharmaceuticals inks $2.1 billion deal with Chinese firm for MASH treatment, aiming to enhance Rezdiffra's efficacy ...

Against steep odds and well-established paradigms, these four companies have successfully been commercializing their products ...